PathoQuest Appoints Rainer Metzger, Ph.D. as Chairman of the Board of Directors
PARIS, FRANCE – September 1st, 2022 – PathoQuest, a pioneer of next-generation sequencing (NGS)-based testing solutions for the quality control of biologics, today announced the appointment of Dr. Rainer Metzger as the chairman of the company’s Board of Directors. Dr. Metzger’s wide experience in the healthcare industry and his entrepreneurial mindset as a life sciences business developer will be key for PathoQuest ongoing scale-up of its global NGS-based biosafety testing services.
“We could not be more thrilled to welcome Rainer to our board of directors,” said Jean-François Brepson, CEO of PathoQuest. “It is a very important time in the development of our company, as we advance our global footprint with two facilities, in France and the United States of America” continued Mr. Brepson. “He has a deep experience of innovative companies and will help us in our mission to serve our global customers”.
Rainer has been working for over 25 years with Diagnostics and Pharma companies in executive and global positions at QIAGEN, DANAHER, ROCHE, and MOLECULAR DEVICES where he was leading the execution of large service organizations and partnerships in drug discovery and biomarker development, precision medicine including product co-development and commercialization programs with major pharmaceutical and diagnostics companies. Rainer is working in the healthcare and life science industry, leading clinical trials, CRO, and SMO organizations at MEDICOVER, and also acting as a board member for a series of Biotech companies in Europe and the United States of America.
“I am looking forward to contributing to PathoQuest growth and conducting its Board,” commented Dr. Rainer Metzger. Rainer started as a Product Manager for Molecular Devices and has continued as an entrepreneur in the Biotech field where he has founded and managed several biotech companies over more than a decade. Rainer holds a Diploma in natural sciences and genetics and a Ph.D. in Biology from the University of Heidelberg.
PathoQuest offers biopharmaceutical companies a game-changing genomic approach at R&D, and GMP grades to ensure the biosafety of biologics like cell and gene therapy products, vaccines, and recombinant drugs. PathoQuest biosafety solutions comprise a portfolio of viral safety and genetic characterization services enabling a reduction in the time to market for these innovative treatments. PathoQuest’s technology combines an NGS platform with proprietary sample preparation processes followed by an automated analysis pipeline using the company’s proprietary pathogen genome sequences databases. PathoQuest entered into a strategic partnership with Charles River Laboratory (Boston, USA) in 2018.
For more information, visit www.pathoquest.com or contact us at email@example.com